Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long-Term Outcome

Federico Lussana, Tamara Intermesoli, Francesca Gianni, Cristina Boschini, Arianna Masciulli, Orietta Spinelli, Elena Oldani, Manuela Tosi, Anna Grassi, Margherita Parolini, Ernesta Audisio, Chiara Cattaneo, Roberto Raimondi, Emanuele Angelucci, Irene Maria Cavattoni, Anna Maria Scattolin, Agostino Cortelezzi, Francesco Mannelli, Fabio Ciceri, Daniele MatteiErika Borlenghi, Elisabetta Terruzzi, Claudio Romani, Renato Bassan, Alessandro Rambaldi

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Allogeneic stem cell transplantation (alloHSCT) in first complete remission (CR1) remains the consolidation therapy of choice in Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL). The prognostic value of measurable levels of minimal residual disease (MRD) at time of conditioning is a matter of debate. We analyzed the predictive relevance of MRD levels before transplantation on the clinical outcome of Ph+ ALL patients treated with chemotherapy and imatinib in 2 consecutive prospective clinical trials. MRD evaluation before transplantation was available for 65 of the 73 patients who underwent an alloHSCT in CR1. A complete or major molecular response at time of conditioning was achieved in 24 patients (37%), whereas 41 (63%) remained carriers of any other positive MRD level in the bone marrow. MRD negativity at time of conditioning was associated with a significant benefit in terms of risk of relapse at 5 years, with a relapse incidence of 8% compared with 39% for patients with MRD positivity (P = .007). However, thanks to the post-transplantation use of tyrosine kinase inhibitors (TKIs), disease-free survival was 58% versus 41% (P = .17) and overall survival was 58% versus 49% (P = .55) in MRD-negative compared with MRD-positive patients, respectively. The cumulative incidence of nonrelapse mortality was similar in the 2 groups. Achieving a complete molecular remission before transplantation reduces the risk of leukemia relapse even though TKIs may still rescue some patients relapsing after transplantation.

Original languageEnglish
Pages (from-to)1983-1987
Number of pages5
JournalBiology of Blood and Marrow Transplantation
Volume22
Issue number11
DOIs
Publication statusPublished - Nov 1 2016

Fingerprint

Residual Neoplasm
Stem Cell Transplantation
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Recurrence
Transplantation
Protein-Tyrosine Kinases
Incidence
Disease-Free Survival
Leukemia
Bone Marrow
Clinical Trials
Drug Therapy
Survival
Mortality

Keywords

  • Acute lymphoblastic leukemia
  • Allogeneic transplantation
  • Minimal residual disease (MRD)

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia : Impact on Relapse and Long-Term Outcome. / Lussana, Federico; Intermesoli, Tamara; Gianni, Francesca; Boschini, Cristina; Masciulli, Arianna; Spinelli, Orietta; Oldani, Elena; Tosi, Manuela; Grassi, Anna; Parolini, Margherita; Audisio, Ernesta; Cattaneo, Chiara; Raimondi, Roberto; Angelucci, Emanuele; Cavattoni, Irene Maria; Scattolin, Anna Maria; Cortelezzi, Agostino; Mannelli, Francesco; Ciceri, Fabio; Mattei, Daniele; Borlenghi, Erika; Terruzzi, Elisabetta; Romani, Claudio; Bassan, Renato; Rambaldi, Alessandro.

In: Biology of Blood and Marrow Transplantation, Vol. 22, No. 11, 01.11.2016, p. 1983-1987.

Research output: Contribution to journalArticle

Lussana, F, Intermesoli, T, Gianni, F, Boschini, C, Masciulli, A, Spinelli, O, Oldani, E, Tosi, M, Grassi, A, Parolini, M, Audisio, E, Cattaneo, C, Raimondi, R, Angelucci, E, Cavattoni, IM, Scattolin, AM, Cortelezzi, A, Mannelli, F, Ciceri, F, Mattei, D, Borlenghi, E, Terruzzi, E, Romani, C, Bassan, R & Rambaldi, A 2016, 'Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long-Term Outcome', Biology of Blood and Marrow Transplantation, vol. 22, no. 11, pp. 1983-1987. https://doi.org/10.1016/j.bbmt.2016.07.021
Lussana, Federico ; Intermesoli, Tamara ; Gianni, Francesca ; Boschini, Cristina ; Masciulli, Arianna ; Spinelli, Orietta ; Oldani, Elena ; Tosi, Manuela ; Grassi, Anna ; Parolini, Margherita ; Audisio, Ernesta ; Cattaneo, Chiara ; Raimondi, Roberto ; Angelucci, Emanuele ; Cavattoni, Irene Maria ; Scattolin, Anna Maria ; Cortelezzi, Agostino ; Mannelli, Francesco ; Ciceri, Fabio ; Mattei, Daniele ; Borlenghi, Erika ; Terruzzi, Elisabetta ; Romani, Claudio ; Bassan, Renato ; Rambaldi, Alessandro. / Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia : Impact on Relapse and Long-Term Outcome. In: Biology of Blood and Marrow Transplantation. 2016 ; Vol. 22, No. 11. pp. 1983-1987.
@article{d1eacdb7e2cf480d9f219d04eb2009d2,
title = "Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long-Term Outcome",
abstract = "Allogeneic stem cell transplantation (alloHSCT) in first complete remission (CR1) remains the consolidation therapy of choice in Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL). The prognostic value of measurable levels of minimal residual disease (MRD) at time of conditioning is a matter of debate. We analyzed the predictive relevance of MRD levels before transplantation on the clinical outcome of Ph+ ALL patients treated with chemotherapy and imatinib in 2 consecutive prospective clinical trials. MRD evaluation before transplantation was available for 65 of the 73 patients who underwent an alloHSCT in CR1. A complete or major molecular response at time of conditioning was achieved in 24 patients (37{\%}), whereas 41 (63{\%}) remained carriers of any other positive MRD level in the bone marrow. MRD negativity at time of conditioning was associated with a significant benefit in terms of risk of relapse at 5 years, with a relapse incidence of 8{\%} compared with 39{\%} for patients with MRD positivity (P = .007). However, thanks to the post-transplantation use of tyrosine kinase inhibitors (TKIs), disease-free survival was 58{\%} versus 41{\%} (P = .17) and overall survival was 58{\%} versus 49{\%} (P = .55) in MRD-negative compared with MRD-positive patients, respectively. The cumulative incidence of nonrelapse mortality was similar in the 2 groups. Achieving a complete molecular remission before transplantation reduces the risk of leukemia relapse even though TKIs may still rescue some patients relapsing after transplantation.",
keywords = "Acute lymphoblastic leukemia, Allogeneic transplantation, Minimal residual disease (MRD)",
author = "Federico Lussana and Tamara Intermesoli and Francesca Gianni and Cristina Boschini and Arianna Masciulli and Orietta Spinelli and Elena Oldani and Manuela Tosi and Anna Grassi and Margherita Parolini and Ernesta Audisio and Chiara Cattaneo and Roberto Raimondi and Emanuele Angelucci and Cavattoni, {Irene Maria} and Scattolin, {Anna Maria} and Agostino Cortelezzi and Francesco Mannelli and Fabio Ciceri and Daniele Mattei and Erika Borlenghi and Elisabetta Terruzzi and Claudio Romani and Renato Bassan and Alessandro Rambaldi",
year = "2016",
month = "11",
day = "1",
doi = "10.1016/j.bbmt.2016.07.021",
language = "English",
volume = "22",
pages = "1983--1987",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "11",

}

TY - JOUR

T1 - Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia

T2 - Impact on Relapse and Long-Term Outcome

AU - Lussana, Federico

AU - Intermesoli, Tamara

AU - Gianni, Francesca

AU - Boschini, Cristina

AU - Masciulli, Arianna

AU - Spinelli, Orietta

AU - Oldani, Elena

AU - Tosi, Manuela

AU - Grassi, Anna

AU - Parolini, Margherita

AU - Audisio, Ernesta

AU - Cattaneo, Chiara

AU - Raimondi, Roberto

AU - Angelucci, Emanuele

AU - Cavattoni, Irene Maria

AU - Scattolin, Anna Maria

AU - Cortelezzi, Agostino

AU - Mannelli, Francesco

AU - Ciceri, Fabio

AU - Mattei, Daniele

AU - Borlenghi, Erika

AU - Terruzzi, Elisabetta

AU - Romani, Claudio

AU - Bassan, Renato

AU - Rambaldi, Alessandro

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Allogeneic stem cell transplantation (alloHSCT) in first complete remission (CR1) remains the consolidation therapy of choice in Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL). The prognostic value of measurable levels of minimal residual disease (MRD) at time of conditioning is a matter of debate. We analyzed the predictive relevance of MRD levels before transplantation on the clinical outcome of Ph+ ALL patients treated with chemotherapy and imatinib in 2 consecutive prospective clinical trials. MRD evaluation before transplantation was available for 65 of the 73 patients who underwent an alloHSCT in CR1. A complete or major molecular response at time of conditioning was achieved in 24 patients (37%), whereas 41 (63%) remained carriers of any other positive MRD level in the bone marrow. MRD negativity at time of conditioning was associated with a significant benefit in terms of risk of relapse at 5 years, with a relapse incidence of 8% compared with 39% for patients with MRD positivity (P = .007). However, thanks to the post-transplantation use of tyrosine kinase inhibitors (TKIs), disease-free survival was 58% versus 41% (P = .17) and overall survival was 58% versus 49% (P = .55) in MRD-negative compared with MRD-positive patients, respectively. The cumulative incidence of nonrelapse mortality was similar in the 2 groups. Achieving a complete molecular remission before transplantation reduces the risk of leukemia relapse even though TKIs may still rescue some patients relapsing after transplantation.

AB - Allogeneic stem cell transplantation (alloHSCT) in first complete remission (CR1) remains the consolidation therapy of choice in Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL). The prognostic value of measurable levels of minimal residual disease (MRD) at time of conditioning is a matter of debate. We analyzed the predictive relevance of MRD levels before transplantation on the clinical outcome of Ph+ ALL patients treated with chemotherapy and imatinib in 2 consecutive prospective clinical trials. MRD evaluation before transplantation was available for 65 of the 73 patients who underwent an alloHSCT in CR1. A complete or major molecular response at time of conditioning was achieved in 24 patients (37%), whereas 41 (63%) remained carriers of any other positive MRD level in the bone marrow. MRD negativity at time of conditioning was associated with a significant benefit in terms of risk of relapse at 5 years, with a relapse incidence of 8% compared with 39% for patients with MRD positivity (P = .007). However, thanks to the post-transplantation use of tyrosine kinase inhibitors (TKIs), disease-free survival was 58% versus 41% (P = .17) and overall survival was 58% versus 49% (P = .55) in MRD-negative compared with MRD-positive patients, respectively. The cumulative incidence of nonrelapse mortality was similar in the 2 groups. Achieving a complete molecular remission before transplantation reduces the risk of leukemia relapse even though TKIs may still rescue some patients relapsing after transplantation.

KW - Acute lymphoblastic leukemia

KW - Allogeneic transplantation

KW - Minimal residual disease (MRD)

UR - http://www.scopus.com/inward/record.url?scp=84992393687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992393687&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2016.07.021

DO - 10.1016/j.bbmt.2016.07.021

M3 - Article

AN - SCOPUS:84992393687

VL - 22

SP - 1983

EP - 1987

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 11

ER -